通过将Abemaciclib与Desipramine相结合,对抗瘤效果的协同增强
Yan Li1, Yeojin Sung2, Young Eun Choi2
1Division of Technology Convergence, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Gyeonggi-Do, Republic of Korea.
这项研究探讨了将循环素依赖性激酶4和6 (CDK4/6) 抑制剂与抗抑郁药物的结合. 这种新的组合显示出协同作用的抗癌效应,并减少了模型中的瘤大小,这表明了对固体瘤的潜在新疗法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 像abemaciclib这样的循环素依赖性激酶4和6 (CDK4/6) 抑制剂对激素受体阳性,HER2阴性晚期乳腺癌有效.
- 副作用,包括间歇性肺病,限制CDK4/6抑制剂的使用,目前的组合疗法也有局限性.
- 需要新的策略来提高CDK4/6抑制剂的疗效和减少副作用.
研究的目的:
- 研究将CDK4/6抑制剂与三环抗抑郁药结合用于癌症治疗的潜力.
- 评估abemaciclib和desipramine联合治疗的协同抗癌作用和安全性.
主要方法:
- 在实验室中测试了abemaciclib和desipramine在H460,MCF7和HCT-116癌细胞系中的疗效.
- 在结肠瘤异种移植模型中评估了abemaciclib和desipramine联合抗瘤作用.
- 在体内评估了瘤大小的减少和毒性.
主要成果:
- 试验室研究表明,组合疗法具有协同作用的抗癌作用,特别是在HCT-116细胞系中.
- 与单一治疗或体内对照相比,组合治疗显著减少了瘤大小.
- 在动物模型中,联合疗法对正常组织没有明显的毒性.
结论:
- 阿贝马西利布和德西普拉的组合显示出有前途的协同作用的抗癌活性.
- 这种新型组合疗法可能提供一种策略,以提高CDK4/6抑制剂对固体瘤的疗效和减少副作用.
- 需要进一步的体内研究来验证这些发现.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
相关概念视频
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Agonism and Antagonism: Quantification
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Antidepressant Drugs: MAOIs and Other Agents
Targeted Cancer Therapies
There are several types of targeted therapies against...
